ArticleBMC complementary medicine and therapies2026
Neuritogenic effects of Ulva lactuca aqueous extract on Neuro-2a cells.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundNeurodegenerative diseases are characterized by progressive neuronal loss and impaired neural connectivity, and effective strategies to promote neuronal regeneration remain limited. In particular, there is a lack of well-characterized neuritogenic agents, highlighting the need for novel candidates. Marine-derived natural products have garnered attention owing to their structural diversity and biological activities. Ulva lactuca, a green macroalga rich in bioactive compounds such as sulfated polysaccharides and phenolics, exhibits various biological effects; however, its neuritogenic potential has not been systematically investigated.
methodsN2a cells were treated for 48 h with graded concentrations of aqueous U. lactuca extract, either alone or in combination with nerve growth factor (NGF), to evaluate neuritogenic activity. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, while neurite outgrowth was quantified by counting neurite-bearing cells. Neuronal differentiation was further evaluated using α-tubulin immunofluorescence staining.
resultsThe extract significantly enhanced N2a cell viability and neurite outgrowth at optimal concentrations. Treatment with 5 mg/mL extract increased the proportion of neurite-bearing cells by 8.51%, which was further increased to 14.21% in combination with NGF. In contrast, higher concentrations (≥ 10 mg/mL) of the extract attenuated neuritogenic responses, indicating a biphasic dose-dependent effect.
conclusionsThese findings suggest that the aqueous extract of U. lactuca may contain bioactive constituents capable of promoting neurite initiation and elongation in vitro. At appropriate concentrations, U. lactuca extract can serve as a potential natural source for neuritogenic agents, warranting further investigation into its underlying mechanisms and active components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.